Comparative effectiveness is gaining momentum as a way to decide what drugs and devices should be used by doctors. But why was it part of the economic stimulus approved by Congress and pushed by President Obama? Dr. Les Paul, vice president of clinical and scientific affairs at the National Pharmaceutical Council, tells the Chicago Tribune's Bruce Japsen about how policymakers are looking at comparative effectiveness and how medical care providers and the healthcare industry should be involved.
Comparative Effectiveness and the Economic Stimulus Package
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Comparative effectiveness is gaining momentum as a way to decide what drugs and devices should be used by doctors. But why was it part of the economic stimulus approved by Congress and pushed by President Obama? Dr. Les Paul, vice president of clinical and scientific affairs at the National Pharmaceutical Council, tells the Chicago Tribune's Bruce Japsen about how policymakers are looking at comparative effectiveness and how medical care providers and the healthcare industry should be involved.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
0.25 credits
<p>Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
0.25 credits
<p>IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy</p>
CME/CE
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
0.25 credits
<p>IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
Project Oncology®
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
<p>HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)</p>
MinuteCE®
Second-line Chemotherapy Options in Metastatic PDAC
0.25 credits
<p>Second-line Chemotherapy Options in Metastatic PDAC</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?